-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
IceCure Medical Ltd Expected to Earn FY2026 Earnings of $0.03 Per Share (NASDAQ:ICCM)
IceCure Medical Ltd Expected to Earn FY2026 Earnings of $0.03 Per Share (NASDAQ:ICCM)
IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) – Analysts at Brookline Capital Management reduced their FY2026 earnings per share (EPS) estimates for shares of IceCure Medical in a report released on Friday, December 30th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of $0.03 for the year, down from their previous forecast of $0.04. The consensus estimate for IceCure Medical's current full-year earnings is ($0.42) per share.
Get IceCure Medical alerts:Separately, Maxim Group began coverage on shares of IceCure Medical in a report on Tuesday, October 25th. They issued a "buy" rating and a $3.00 target price on the stock.
IceCure Medical Trading Up 5.4 %
IceCure Medical stock opened at $1.55 on Monday. IceCure Medical has a 52-week low of $0.75 and a 52-week high of $4.73. The business has a 50-day simple moving average of $1.18 and a two-hundred day simple moving average of $1.45. The company has a market cap of $70.72 million, a P/E ratio of -3.44 and a beta of 0.33. The company has a quick ratio of 3.58, a current ratio of 4.22 and a debt-to-equity ratio of 0.03.IceCure Medical (NASDAQ:ICCM – Get Rating) last posted its earnings results on Monday, December 5th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). IceCure Medical had a negative net margin of 462.46% and a negative return on equity of 77.00%.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in IceCure Medical stock. JPMorgan Chase & Co. bought a new stake in IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,240 shares of the company's stock, valued at approximately $78,000.
About IceCure Medical
(Get Rating)
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Featured Articles
- Get a free copy of the StockNews.com research report on IceCure Medical (ICCM)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) – Analysts at Brookline Capital Management reduced their FY2026 earnings per share (EPS) estimates for shares of IceCure Medical in a report released on Friday, December 30th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of $0.03 for the year, down from their previous forecast of $0.04. The consensus estimate for IceCure Medical's current full-year earnings is ($0.42) per share.
Icecure Medical Ltd（纳斯达克股票代码：ICCM — 获取评级）——布鲁克林资本管理公司的分析师在12月30日星期五发布的一份报告中下调了对Icecure Medical股票的 FY2026 每股收益（EPS）的预期。Brookline Capital Management分析师K. Dolliver现在预计，该公司今年的每股收益将为0.03美元，低于他们之前预测的0.04美元。对Icecure Medical当前全年收益的共识估计为每股收益（0.42美元）。
Separately, Maxim Group began coverage on shares of IceCure Medical in a report on Tuesday, October 25th. They issued a "buy" rating and a $3.00 target price on the stock.
另外，Maxim集团在10月25日星期二的一份报告中开始报道IceCure Medical的股票。他们对该股发布了 “买入” 评级和3.00美元的目标价格。
IceCure Medical Trading Up 5.4 %
iCecure 医疗交易上涨5.4％
IceCure Medical (NASDAQ:ICCM – Get Rating) last posted its earnings results on Monday, December 5th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). IceCure Medical had a negative net margin of 462.46% and a negative return on equity of 77.00%.
Icecure Medical（纳斯达克股票代码：ICCM — 获取评级）最后一次公布财报是在12月5日星期一。该公司公布了本季度每股收益（0.11美元），达到了共识预期（0.11美元）。Icecure Medical的净利润率为负462.46％，负股本回报率为77.00％。
Institutional Inflows and Outflows
机构流入和流出
A hedge fund recently bought a new stake in IceCure Medical stock. JPMorgan Chase & Co. bought a new stake in IceCure Medical Ltd (NASDAQ:ICCM – Get Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,240 shares of the company's stock, valued at approximately $78,000.
一家对冲基金最近购买了IceCure Medical股票的新股份。摩根大通向美国证券交易委员会提交的最新13F表文件显示，摩根大通在第二季度收购了iCecure Medical Ltd（纳斯达克股票代码：ICCM — Get Rating）的新股份。该机构投资者购买了该公司7,240股股票，价值约78,000美元。
About IceCure Medical
关于 iceCure Med
(Get Rating)
（获取评分）
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
IceCure Medical Ltd是一家医疗器械公司，从事用于冷冻消融（冻结）人体肿瘤的医疗器械的研究、开发和商业化。它提供ProSense系统，一种用于治疗乳腺肿瘤的冷冻消融解决方案。该公司成立于2006年，总部位于以色列凯撒利亚。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on IceCure Medical (ICCM)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
- 免费获取 StockNews.com 关于 Icecure Medical (ICCM) 的研究报告的副本
- MarketBeat：本周回顾 12 月 26 日 — 12 月 30 日
- 科技之狗：是时候咬一口这些股票了
- 此次收购会使微软成为熊市买入吗？
- 你应该为冬天的 Generac Stock 做热身吗？
- 金塔拉疗法是隐藏的宝石吗？
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接收《iceCure医学日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Icecure Medical及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧